Purpose: The combination of Gemcitabine (GEM)/carboplatin (CBDCA) has demonstrated activity in the treatment of stage III and IV non-small-cell lung cancer (NSCLC). This phase III randomized trial compared the response rate, survival rate, and toxicity of the combination of GEM plus CBDCA with...
Purpose: The combination of Gemcitabine (GEM)/carboplatin (CBDCA) has demonstrated activity in the treatment of stage III and IV non-small-cell lung cancer (NSCLC). This phase III randomized trial compared the response rate, survival rate, and toxicity of the combination of GEM plus CBDCA with...
The combination of Gemcitabine (GEM)/carboplatin (CBDCA) has demonstrated activity in the treatment of stage III and IV non-small-cell lung cancer (NSCLC). This phase III randomized trial compared the response rate, survival rate, and toxicity of the combination of GEM plus CBDCA with the comb...
Combination chemotherapy with carboplatin (CBDCA), docetaxel (DOC) and gemcitabine (GEM) in advanced non-small cell lung cancer (NSCLC). A phase II studyHumansCarcinoma, Non-Small-Cell LungLung NeoplasmsTaxoidsPaclitaxelCarboplatinDeoxycytidineTreatment Outcome...
P1.01-08 Randomized Phase II Trial of CBDCA+nab-PTX vs CDDP+GEM in Patients with Chemo-Nave Squamous Cell Lung Cancer: NJLCG1302doi:10.1016/j.jtho.2019.08.723T. HaradaY. KawashimaY. FujitaT. NakagawaK. WatanabeN. MorikawaK. Takamura...
Methods Chemo-nave stage IIIB/IV or postoperative recurrent SCC pts were randomly assigned to receive either cisplatin (80 mg/m2) on day 1 plus gemcitabine (1000 mg/m2) on days 1, 8 every 3 weeks or CBDCA (AUC 6 mg/ml/min) on day 1 plus nab-PTX (75 mg/m2) on days 1, 8, ...